Advanced search×

[Problem of neuromuscular block reversion: neostigmine and sugammadex].

V M VM Mizikov, V I VI Stamov, Iu V IuV Deshko, and A Iu AIu Ialich

Anesteziol Reanimatol (2010) PMID 20524330

The review covers the history of neuromuscular block reversal. It states that indications for decurarization have been changed due to the extremely high rate of residual curarization even after the use of average-acting myorelaxants. The paper provides the pharmacological characteristics of sugammadex, a new selective relaxant-binding agent for aminosteroids (rocuronium and vecuronium) with the unique mechanism of action. It also gives data on the efficacy and safety of sugammadex versus anticholinesterase agents and estimates the prospects for its clinical application.

Version: za2963e q8za1 q8zb2 q8zcf q8zd7 q8ze2 q8zf7 q8zga
Buy PDF

Similar articles you may find interesting…

  1. [Sugammadex (Org 25969, modified gamma-cyclodextrin)].
    Takahiro T Suzuki

    Masui 55(7):834-40 (2006) PMID 16856543

    Sugammadex, a chemically modified gamma-cyclodextrin, was synthesized as a selective reversal agent for rocuronium, a steroidal neuromuscular blocking agent. The lipophilic cavity of sugammadex molecule encapsulates the lipophilic steroid rings of rocuronium and forms 1:1 host-guest complex. Additio...
    Buy PDF
  2. Terahertz lenses made by compression molding of micropowders.
    Benedikt B Scherger, Maik M Scheller, ... Karin K Wiesauer

    Appl Opt 50(15):2256-62 (2011) PMID 21614120

    We present a simple and versatile approach for fabricating terahertz lenses based on compression molding of micropowder polymer materials in a tabletop hydraulic press. To demonstrate the feasibility of this approach, a biconvex lens shape is calculated using a ray-tracing algorithm and lenses based...
    Buy PDF
  3. Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-i...
    F F Ortu, L E LE Weimer, ... P E PE Manconi

    European Journal of Medical Research 15(2):81-3 (2010) PMID 20452889 PMCID PMC3352050

    given the relatively common prevalence of HCV-related chronic hepatitis among people with HIV, raltegravir might represent an important alternative option for a substantial number of patients who cannot be treated with protease inhibitors or NNRTI because of drug-related hepatic toxicity....
    View PDF